Valvular Abnormalities and Cardiovascular Status Following Exposure to Dexfenfluramine or Phentermine/Fenfluramine

Evaluating cardiovascular status and the prevalence of valvular abnormalities, as assessed by clinical cardiovascular parameters and echocardiography, in patients treated for obesity with dexfenfluramine or phentermine/fen Fluramine indicates that use of dexfinfluramines and phentermin/fen fluramine is associated with an increase in the prevalenceof AR, but was not associated with a increase inThe prevalence of MR using FDA criteria or with serious cardiac events.

Abstract

Our data indicate that use of dexfenfluramine and phentermine/fenfluramine is associated with an increase in the prevalence of AR using FDA echocardiographic criteria, but was not associated with an increase in the prevalence of MR using FDA criteria or with serious cardiac events.